Apixaban tablets (2.5 mg) were obtained from Zhejiang Yongning Pharmaceutical Co., Ltd. (test formulation) and Bristol‐Myers Squibb Company (Eliquis, reference formulation).
Protocol detail
Bioavailability of Apixaban Tablets
Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link:
Access Free Full Text.
Corresponding Organization : Second Affiliated Hospital of Zhejiang University
Top 5 similar protocols
Variable analysis
independent variables
- Formulation type (test formulation vs. reference formulation)
- Not explicitly mentioned
- Apixaban tablets (2.5 mg)
- Positive control: Eliquis (reference formulation)
- Negative control: Not mentioned
Annotations
This protocol is too short. Unable to provide accurate annotations
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!